RGNT

NYSEAMERICAN 已收盘

Regentis Biomaterials Ltd.

2.06 USD
+0.13+10.16%
2026-08-03
市值
$10.67M
市盈率
EPS
-24.16
股息率
52 周区间
1.23 – 15.50
成交量
115.67K
Beta
目标价
52W 低 1.2352W 高 15.50
价格走势

公司简介

Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee. The company was incorporated in 2004 and is based in Herzliya, Israel.